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o● PURPOSE: To determine if small hard drusen in pa-
tients with basal laminar drusen show short-term
changes.
● DESIGN: Prospective observational case series.
● METHODS: Ten subjects with basal laminar drusen
ere longitudinally followed during a period of 4 months
y spectral-domain optical coherence tomography. Drusen
hat showed a spontaneous change in volume were further
nalyzed according to 5 morphologic parameters: shape,
eflectivity, homogeneity, and concurring photoreceptor
ayer/retinal pigment epithelium damage. Odds ratios
OR) and risk for regression and progression of drusen
olumes were calculated.
● RESULTS: One hundred and five small hard drusen in
19 eyes showed a spontaneous change in volume over the
period of follow-up. Drusen with a “pointed” shape were
significantly associated (P  .031; OR 4.89; 95%
confidence interval [CI] 1.1620.67) with spontaneous
progression in drusen volume, with a chance of 0.80
(95% CI 0.550.93) to progress. Drusen that showed a
decreased reflectivity of overlying photoreceptor layer
(P  .041; OR 7.67; 95% CI 1.0954.24) or retinal
pigment epithelium (P  .022; OR 12.38; 95% CI
1.44106.57), showed a significant association with
spontaneous regression in drusen volume, with chances
of regression of 0.86 (95% CI 0.410.98) and 0.89
(95% CI 0.490.99), respectively.
● CONCLUSION: Small hard drusen in patients with the
asal laminar drusen phenotype are subject to a process
f short-term remodeling. The dynamic nature of this
isease points to high biochemical activity that may be
ensitive to future pharmacologic treatment strategies. In
ddition, these short-term changes of drusen may be a
ource of misclassification in disease staging. (Am J
phthalmol 2012;154:560–567. © 2012 by Elsevier
nc. )
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© 2012 BY ELSEVIER INC.60 OM ACULAR DRUSEN ARE THE HALLMARK LESIONSof age-related macular degeneration (AMD).1,2They are identified on ophthalmoscopy as focal
yellow-white subretinal deposits, which are pathologic
extracellular deposits between the basal lamina of the
retinal pigment epithelium (RPE) and the inner collage-
nous layer of Bruch membrane.3–5 Drusen contain a wide
variety of compounds that appear to reflect the complex
pathogenesis of AMD. Important constituents of drusen
are neutral lipids,6,7 carbohydrates,8 zinc,9 and a wide
variety of proteins. Many proteins found in drusen are
associated with inflammation and/or immune-associated
processes, including a broad spectrum of complement
components.10,11 In addition, associations between AMD
nd genetic variants in complement genes have been
eported, which supports the role of low-grade inflamma-
ion and an abnormal regulation of the complement system
n drusen pathogenesis.12–20 Drusen are an important
quantifier of the severity of AMD. Therefore, the size and
number of drusen are used for AMD staging and for the
prediction of the likelihood of disease progression and
vision loss.1,2,21
Different clinical subtypes of drusen have been described
in AMD, but all drusen seem to be indistinguishable in
location, composition, and substructure.5 “Basal laminar
drusen,” also termed “cuticular drusen,” refers to an early-
onset drusen phenotype with innumerable small (25 to 75
m) hard drusen.22,23 This subtype of AMD is more easily
isualized angiographically than biomicroscopically, with a
ypical “stars-in-the-sky” appearance during the early arte-
iovenous phase of fluorescein angiography (Figure 1).24 In
ater stages, the number of drusen often increases, with
lustered groups of drusen scattered throughout the ret-
na.22
In general, color fundus photographs are used to evalu-
ate the morphology of drusen over time. However, color
images do not provide detailed information about the
changing morphology of small drusen.25–27 The introduc-
ion of spectral-domain optical coherence tomography
SD-OCT) has enabled an improved in vivo visualization
f drusen morphology.28 SD-OCT is able to acquire
3-dimensional images of the retina with high speed and
high resolution. Subsequently, studies of the fine details of
small drusen and adjacent retinal structures become possi-
ble.28,29
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phology in routinely followed eyes with basal laminar
drusen, we decided to longitudinally investigate the ap-
pearance of small hard drusen in eyes with this phenotype.
The focus of our investigation was to determine whether
morphologic parameters may be predictive for processes of
progression or regression of small hard drusen in basal
laminar drusen affected eyes.
PATIENTS AND METHODS
● PATIENTS: A total of 10 subjects who met the diagnos-
ic criteria of basal laminar drusen were retrieved from the
uropean Genetic Database (EUGENDA, www.eugenda.
rg), a large multicenter database for clinical and molec-
lar analysis of AMD and different early-onset drusen
henotypes.
For inclusion in the study, subjects had basal laminar
rusen of the posterior pole and ocular media allowing
dequate SD-OCT scanning, defined by a maximum score
f NO3/NC2/C1/P1 according the Lens Opacities Classi-
cation System III.30 Study participants had to be able to
fixate for at least 1 minute per eye to allow adequate
SD-OCT scanning. The basal laminar drusen phenotype
was defined as a symmetrically distributed pattern between
both eyes of at least 50 scattered, uniformly sized, small (25
m to 75 m), hyperfluorescent drusen on fluorescein
angiography in each eye, of which at least 20 drusen are
located outside the Wisconsin age-related maculopathy
grading template.31 Eyes with choroidal neovascularization
(CNV), a large area of central geographic atrophy (1500
m), and retinal abnormalities other than AMD-related
FIGURE 1. Fluorescein angiographic photograph of the left eye
of a 45-year-old patient with basal laminar drusen.were excluded from the study. In order to exclude possible
SHORT-TERM CHANGES OF BASALOL. 154, NO. 3effects of antioxidant agent use on changing drusen morphol-
ogy, the use of antioxidant agents was prohibited 1 month
FIGURE 2. Drusen volume at regression in a patient with basal
laminar drusen recorded by spectral-domain optical coherence
tomography (SD-OCT). (Top) Baseline: Homogeneous, dome-
shaped hard drusen (white arrow heads) without damage of the
overlying retinal pigment epithelium or photoreceptor layer. (Mid-
dle) After 2 months of follow-up. (Bottom) After 4 months of
follow-up; note the total regression of the hard drusen (black
arrow heads) without detectable changes on SD-OCT at the
former areas of homogeneous, dome-shaped hard drusen.prior to study entry and during the follow-up period.
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B● IMAGE ACQUISITION: All study participants were ex-
amined 3 times with a 2-month interval during a follow-up
period of 4 months. During each visit, visual acuity was
FIGURE 3. Druse showing volume progression in a patient
with basal laminar drusen recorded by spectral-domain optical
coherence tomography (SD-OCT). (Top) Baseline: A homoge-
neous, very small dome-shaped hard druse (white arrowhead)
without overlying retinal pigment epithelium or photoreceptor
layer damage. (Middle) After 2 months follow-up and (Bottom)
after 4 months follow-up: Progression towards a larger druse
(black arrow head) is seen.recorded with Early Treatment Diabetic Retinopathy
AMERICAN JOURNAL OF562Study (ETDRS) charts. Multimodal imaging was performed
by a combined confocal scanning laser ophthalmoscope
(cSLO)/SD-OCT device (SPECTRALIS; Heidelberg Engi-
neering, Heidelberg, Germany) after pupil dilation with 1
drop of 2.5% phenylephrine hydrochloride and 1 drop of 1%
tropicamide. A standardized imaging protocol was performed
in each study eye, which included near-infrared reflectance
imaging in high-speed mode (  815 nm; scan angle, 30
degrees; image resolution, 768  768 pixels) and simultane-
ous SD-OCT scanning (  870 nm; 40 000 A-scans per
second; number of B-scans, 38; distance between B-scans, 122
m) using a second, independent pair of scanning mirrors.
Because of the independent pairs of scanning mirrors, eye
movements were registered and corrected automatically (“eye
tracking”) by the cSLO/SD-OCT device. The eye tracker
enabled the identification of the same scanning location during
follow-up visits. By this means, a very high repeatability and
reproducibility of longitudinal measurements with an exceed-
ingly small measurable change (1.5 m) of retinal structure has
been shown for this device.32 Therefore, a highly reliable
comparison of drusen as small as 25 to 75 m, like in basal
aminar drusen, is possible on follow-up OCT scans.
To increase image quality, the Automatic Real-Time
ART) function was used. With ART activated, 35 SD-
CT B-scans of the same scanning location were per-
ormed during the scanning process and images were
veraged for noise reduction.
● IMAGE ANALYSIS: For the morphologic evaluation of
the small hard drusen, baseline SD-OCT scans and SD-
OCT scans after 4 months were studied side by side by 2
graders (J.vd.V. and Y.L.). Only drusen that showed
increasing volume over time or decreasing volume over
time were analyzed for this study (Figures 2 and 3). The
analysis focused on 5 morphologic parameters (Figure 4),
partly adopted from Khanifar and associates,33 with the
additional parameters for photoreceptor layer and RPE
layer damage, scored as follows: the shape of the drusen was
characterized as dome-shaped (basal diameter  height),
pointed (basal diameter  height), or saw-toothed
grouped pointed drusen edging each other at the level of
ruch membrane); the predominant internal reflectivity
between RPE elevation and the Bruch membrane was
characterized as low (isoreflective or hyporeflective com-
pared to the photoreceptor outer segment layer), medium
(hyperreflective compared to the photoreceptor outer seg-
ment layer but hyporeflective relative to the RPE), or high
(isoreflective or hyperreflective in relation to the RPE);
the homogeneity of internal drusen reflectivity was char-
acterized as homogeneous (uniform internal reflectivity),
nonhomogeneous with core (varying internal reflectivity
with a distinct single focus of hyperreflectivity), or non-
homogeneous without core (varying internal reflectivity
without a distinct focus of hyperreflectivity); photorecep-
tor layer damage was characterized as present (hyporeflec-
tive photoreceptor layer overlying a druse relative to the
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areas without drusen) or absent (isoreflective photorecep-
tor layer overlying a druse relative to the surrounding
average photoreceptor layer reflectivity); and RPE damage
was characterized as present (hyporeflective RPE overlying
a druse relative to the surrounding average RPE reflectivity
FIGURE 4. Five of the combined morphologic drusen fe
Dome-shaped, medium reflectivity, homogeneous, no retinal
Pointed, medium reflectivity, nonhomogeneous with core,
medium reflectivity, homogeneous, no RPE or photorecepto
photoreceptor layer damage. (Far right) Dome-shaped, mediu
RPE damage.
TABLE. Summary of Drusen Patterns Seen in the Drusen Re
Basic Morpho
Drusen
No. Drusen (%
Shape
Dome 37 (75.5%
Pointed 5 (10.2%
Saw-toothed 7 (14.3%
Reflectivity
Low ( photoreceptor layer) 2 (4.1%)
Medium (between photoreceptor layer and RPE) 47 (95.9%
High (RPE) 0 (0.0%)
Homogeneity
Homogeneous 43 (87.8%
Nonhomogeneous with core 0 (0.0%)
Nonhomogeneous without core 6 (12.2%
Photoreceptor layer damaged
Present 6 (12.2%
Absent 43 (87.8%
RPE damaged
Present 9 (18.2%
Absent 40 (83.3%
n.s.  not significant; RPE  retinal pigment epithelium.
aP value represents the difference in association between the dru
bNo. Eyes represent the total number of eyes out of 19, harborinin retinal areas without drusen) or absent (isoreflective n
SHORT-TERM CHANGES OF BASALOL. 154, NO. 3RPE overlying a druse relative to surrounding average RPE
reflectivity).
● STATISTICS: Statistical analysis was performed by SPSS
tatistical software, version 18.0 (SPSS Inc., Chicago,
llinois, USA). The prevalence (number of eyes and
s seen in patients with basal laminar drusen. (Far left)
ent epithelium (RPE) or photoreceptor layer damage. (Left)
PE or photoreceptor layer damage. (Middle) Saw-toothed,
er damage. (Right) Pointed, medium reflectivity, RPE and
ectivity, homogeneous, photoreceptor layer damage without
ion Group and the Drusen Progression Group, Organized by
Parameters
ssion Group Drusen Progression Group
P ValueaNo. Eyes (%)b No. Drusen (%) No. Eyes (%)b
16 (84.2%) 30 (53.6%) 14 (73.7%) n.s.
3 (15.8%) 20 (35.7%) 10 (52.6%) .031
5 (26.3%) 6 (10.7%) 6 (31.6%) n.s.
2 (10.5%) 1 (1.8%) 1 (5.3%) n.s.
18 (94.7%) 55 (98.2%) 18 (94.7%) n.s.
0 (0.0%) 0 (0.0%) 0 (0.0%) n.s.
19 (100.0%) 51 (91.1%) 17 (89.5%) n.s.
0 (0.0%) 2 (3.6%) 2 (10.5%) n.s.
5 (26.3%) 3 (5.4%) 3 (15.8%) n.s.
4 (21.1%) 1 (1.8%) 1 (5.3%) .041
18 (94.7%) 55 (98.2%) 18 (94.7%)
6 (31.6%) 1 (1.8%) 1 (5.3%) .022
17 (89.5%) 55 (98.2%) 18 (94.7%)
regression group and the drusen progression group.
sen with specific morphologic parameter.ature
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senumber of drusen) of each basic morphologic pattern was
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acalculated and analyzed with descriptive statistics. Drusen
were measured by the Heidelberg Eye Explorer software,
version 1.6.4.0 (Heidelberg Engineering GmbH, Heidel-
berg, Germany), and a ratio between height and basal
diameter was calculated. For interindividual correction, a
model for generalized estimating equations for binary
outcome was used to analyze differences in drusen
characteristics between drusen that showed a progres-
sion in drusen volume (the “drusen progression” group)
and drusen that showed an decreasing drusen volume
(the “drusen regression” group). Strength of association
of the different drusen characteristics between the
“drusen regression” group and “drusen progression”
group is shown as odds ratios (ORs) with a 95%
confidence interval (95% CI). The chance of drusen
morphology change was expressed as a value between 0
(0% chance) and 1.0 (100% chance). Reported P values
re 2-sided and a value of .05 was considered statisti-
ally significant.
RESULTS
SD-OCT WAS PERFORMED ON 19 EYES OF 10 PATIENTS. ONE
eye was excluded from this study because of a large area
of central geographic atrophy. The mean age of the
patients was 64.6  13.9 years, ranging from 45 to 86
ears. Nine patients were female and 1 patient was male.
he mean baseline best-corrected visual acuity was 78
etters (range, 20 to 95). In all eyes visual acuity
emained stable (P  .231) during the period of follow-
p, with a mean increase of 1 letter on the ETDRS
isual acuity chart.
The morphologic results of small hard drusen with
pontaneous volume regression and the morphologic re-
ults of small hard drusen with progression are depicted in
he Table. The most common small hard drusen that
howed short-term changes were homogeneous, dome-
haped drusen with medium internal reflectivity and
ithout overlying RPE or photoreceptor layer damage.
ome-shaped small hard drusen (n  67) showed an
verage base-to-height ratio of 1:0.58, while pointed small
ard drusen (n  25) showed an average base-to-height
atio of 1:1.43. Of the cases with drusen volume regression,
0.6% (15/49) completely regressed during follow-up,
hereas 69.4% (34/49) showed a decreased drusen volume
nly. In cases of small hard drusen with increased drusen
olume, 33.9% (19/56) showed development of new
rusen, whereas 66.1% (37/56) of those small hard drusen
howed an increased drusen volume.
Pointed drusen showed a significant association with a
rogression in volume (P  .031; OR 4.89; 95% CI
.1620.67), with a chance of 0.80 (95% CI 0.550.93)
or volume progression. No significant longitudinal
hanges were observed for dome-shaped and saw-toothed
rusen. Drusen with overlying photoreceptor layer or RPE p
AMERICAN JOURNAL OF564damage showed a statistically significant association with a
regression in volume (P  .041; OR 7.67; 95% CI
1.0954.24 and P  .022; OR 12.38; 95% CI
1.44106.57), with similar chances for drusen volume
regression (0.86 [95% CI 0.410.98] and 0.89 [95% CI
0.490.99], respectively). Drusen reflectivity and homo-
geneity did not appear to have significant impact on drusen
change.
DISCUSSION
IN THIS STUDY, WE WERE ABLE TO SHOW THAT SMALL
hard drusen in patients with the basal laminar drusen
phenotype are subject to a constant dynamic process of
drusen remodeling. The initial drusen morphology
seemed to predict the future course of drusen develop-
ment. Small hard drusen with a decreased reflectivity of
overlying RPE or photoreceptor layer were more likely
to show a regression in drusen volume, whereas pointed
small hard drusen were more likely to show volume
progression.
Although the exact mechanism of drusen biogenesis in
basal laminar drusen as well as in “typical” AMD is still
unclear, an identical mechanism in the developmental
courses may be expected because of the similar topo-
graphic, structural, and compositional features.5 In both
drusen types, RPE cell pathology seems to play a major role
in drusen development. Cellular remnants and debris
derived from degenerated RPE cells become sequestered
between the RPE basal lamina and the inner collagenous
layer of Bruch membrane and provoke a chronic inflam-
matory response with complement activation.34–36 Simul-
aneous with this continuous process of accumulating
xtracellular debris, there is a process of drusen removal
hat may be related to at least 2 factors.
The first is the removal of these drusen constituents
y macrophages.5,10,37 Different types of macrophages
re present in the normal human choroid.38 In contrast
to resident choroidal macrophages, Bruch membrane
macrophages are only seen in eyes with drusen, making
these macrophages a possible player in the process of
drusen regression.39 A role for macrophages in the
process of drusen removal is further supported by animal
models that suggest that an impaired mobilization of
macrophages may prevent the clearance of drusen-like
lesions in mice.40,41
A second mechanism that may explain the removal of
drusen could be an altered function of protein expression
in RPE cells. RPE cells produce and secrete their own
complement inhibitors, such as complement factor H,
complement factor I, membrane cofactor protein, vitro-
nectin, and clusterin.11,42–46 The production of these
complement inhibitors is upregulated in patients with
AMD.42 Furthermore, vitronectin and membrane cofactor
rotein are upregulated in the RPE cells that flank or
OPHTHALMOLOGY SEPTEMBER 2012
Voverlie drusen.11,42 This production of complement inhib-
itors by ocular tissues, like the RPE cell, plays an important
role not only in protecting the eye against complement-
mediated damage but also in maintaining the immune-
privileged state of the eye.47
Disturbance of the aforementioned factors that in-
duce and sustain chronic local inflammation at the level
of the RPE–Bruch membrane interface, and those that
attenuate it, can explain the association of a decreased
reflectivity of the overlying RPE and concomitant pho-
toreceptor layer with drusen regression. A loss of RPE
cells will result in a decreased generation of extracellular
debris that makes up a druse, whereas macrophage
recruitment and the upregulation of complement inhib-
itors by RPE cells flanking the druse will start a process
of druse volume regression. It is this process of drusen
remodeling that points to a high biochemical activity
and suggests that future treatments targeting these
biochemical processes in an early stage of the disease
may have a significant role in prophylactic and thera-
peutic interventions in basal laminar drusen.
The finding that drusen progression and drusen regres-
sion occurred in all the study eyes within a very short
period may have implications for clinical studies on pa-
tients with basal laminar drusen. Because number and size
of drusen are important for disease staging, longitudinal
changes in drusen morphology can be a potential source of
misclassification and needs attention in epidemiologic
studies investigating the natural history of basal laminar
Invest Ophthalmol Vis Sci 2008;49(3):1200–1209.
SHORT-TERM CHANGES OF BASALOL. 154, NO. 3drusen as well in clinical trials evaluating the efficacy of
possible therapies.
Our study has some limitations. First of all, the limited
number of eyes restricts the general use of our data.
However, because drusen remodeling was observed in all
study eyes, those changes are very likely to occur com-
monly in eyes with basal laminar drusen. Secondly, slight
variations of SD-OCT scan positions during follow-up
visits cannot be excluded. However, eye movements were
automatically registered and corrected for “eye tracking,”
resulting in high repeatability and reproducibility of the
SD-OCT scans; therefore, small shifts of only a few
microns could have influenced the appearance of these
very small drusen in basal laminar drusen.29,32 On the
other hand, it is unlikely that random shifts may lead to
nonrandom, continuous changes during the study period.
We included only drusen with increasing or decreasing
drusen volume at all time points (at baseline, after 2
months, and after 4 months) for progression analysis to
further reduce the possibility for such a systematic mea-
surement error.
In summary, we were able to demonstrate that small
hard drusen in patients with basal laminar drusen show a
constant remodeling process. This dynamic process may be
a potential source of misclassification in disease staging at
a single point of time. Changing the balance between the
generation and the elimination of these drusen in an early
stage of the disease may be a new target for therapeutic
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REPORTING VISUAL ACUITIES
The AJO encourages authors to report the visual acuity in the manuscript using the same nomenclature that was used in
gathering the data provided they were recorded in one of the methods listed here. This table of equivalent visual acuities
is provided to the readers as an aid to interpret visual acuity findings in familiar units.
Table of Equivalent Visual Acuity Measurements
Snellen Visual Acuities
Decimal Fraction LogMAR4 Meters 6 Meters 20 Feet
4/40 6/60 20/200 0.10 	1.0
4/32 6/48 20/160 0.125 	0.9
4/25 6/38 20/125 0.16 	0.8
4/20 6/30 20/100 0.20 	0.7
4/16 6/24 20/80 0.25 	0.6
4/12.6 6/20 20/63 0.32 	0.5
4/10 6/15 20/50 0.40 	0.4
4/8 6/12 20/40 0.50 	0.3
4/6.3 6/10 20/32 0.63 	0.2
4/5 6/7.5 20/25 0.80 	0.1
4/4 6/6 20/20 1.00 0.0
4/3.2 6/5 20/16 1.25 0.1
4/2.5 6/3.75 20/12.5 1.60 0.2
4/2 6/3 20/10 2.00 0.3
From Ferris FL III, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982;94:91–96.LAMINAR DRUSEN ON OCT 567
